Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | casein kinase 2, alpha subunit, putative | 0.4547 | 1 | 1 |
Loa Loa (eye worm) | Csnk2b protein | 0.2477 | 0.4586 | 0.4586 |
Trichomonas vaginalis | CMGC family protein kinase | 0.4547 | 1 | 1 |
Trichomonas vaginalis | casein kinase II beta chain, putative | 0.2477 | 0.4586 | 0.4586 |
Trichomonas vaginalis | casein kinase II beta chain, putative | 0.2477 | 0.4586 | 0.4586 |
Toxoplasma gondii | CMGC kinase, CK2 family | 0.4547 | 1 | 1 |
Trichomonas vaginalis | casein kinase II beta chain, putative | 0.2477 | 0.4586 | 0.4586 |
Entamoeba histolytica | casein kinase II regulatory subunit family protein | 0.2477 | 0.4586 | 0.4586 |
Entamoeba histolytica | casein kinase II regulatory subunit family protein | 0.2477 | 0.4586 | 0.4586 |
Echinococcus multilocularis | casein kinase ii subunit alpha | 0.4547 | 1 | 1 |
Trypanosoma brucei | Casein kinase II | 0.4547 | 1 | 1 |
Onchocerca volvulus | Casein kinase II subunit beta homolog | 0.2477 | 0.4586 | 0.5 |
Entamoeba histolytica | casein kinase II regulatory subunit family protein | 0.2477 | 0.4586 | 0.4586 |
Schistosoma mansoni | protein kinase | 0.4547 | 1 | 1 |
Trichomonas vaginalis | casein kinase II beta chain, putative | 0.2477 | 0.4586 | 0.4586 |
Trichomonas vaginalis | CMGC family protein kinase | 0.4547 | 1 | 1 |
Plasmodium vivax | unspecified product | 0.4547 | 1 | 1 |
Trichomonas vaginalis | casein kinase II beta chain, putative | 0.2477 | 0.4586 | 0.4586 |
Onchocerca volvulus | Casein kinase II subunit beta homolog | 0.2477 | 0.4586 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.4547 | 1 | 1 |
Echinococcus granulosus | casein kinase ii subunit alpha | 0.4547 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.4547 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.4547 | 1 | 1 |
Entamoeba histolytica | protein kinase domain containing protein | 0.4547 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.4547 | 1 | 1 |
Loa Loa (eye worm) | CMGC/CK2 protein kinase | 0.4547 | 1 | 1 |
Trichomonas vaginalis | casein kinase II beta chain, putative | 0.2477 | 0.4586 | 0.4586 |
Giardia lamblia | Kinase, CMGC CK2 | 0.4547 | 1 | 1 |
Trichomonas vaginalis | casein kinase II beta chain, putative | 0.2477 | 0.4586 | 0.4586 |
Giardia lamblia | Casein kinase II beta chain | 0.2477 | 0.4586 | 0.4586 |
Trichomonas vaginalis | casein kinase II beta chain, putative | 0.2477 | 0.4586 | 0.4586 |
Brugia malayi | Csnk2b protein | 0.2477 | 0.4586 | 0.4586 |
Trichomonas vaginalis | casein kinase II beta chain, putative | 0.2477 | 0.4586 | 0.4586 |
Trichomonas vaginalis | casein kinase II beta chain, putative | 0.2477 | 0.4586 | 0.4586 |
Trypanosoma cruzi | casein kinase II, putative | 0.4547 | 1 | 1 |
Trichomonas vaginalis | casein kinase II beta chain, putative | 0.2477 | 0.4586 | 0.4586 |
Trichomonas vaginalis | casein kinase II beta chain, putative | 0.2477 | 0.4586 | 0.4586 |
Plasmodium falciparum | casein kinase 2, alpha subunit | 0.4547 | 1 | 1 |
Entamoeba histolytica | casein kinase, putative | 0.4547 | 1 | 1 |
Trichomonas vaginalis | casein kinase II beta chain, putative | 0.2477 | 0.4586 | 0.4586 |
Leishmania major | casein kinase II, putative | 0.4547 | 1 | 1 |
Trichomonas vaginalis | casein kinase II beta chain, putative | 0.2477 | 0.4586 | 0.4586 |
Trichomonas vaginalis | CMGC family protein kinase | 0.4547 | 1 | 1 |
Trichomonas vaginalis | casein kinase II beta chain, putative | 0.2477 | 0.4586 | 0.4586 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MIC (functional) | = 200 ug ml-1 | Antibacterial activity against Escherichia coli MTCC 443 assessed as growth inhibition by broth microdilution method | ChEMBL. | 23644214 |
MIC (functional) | > 1000 ug ml-1 | Antifungal activity against Candida albicans MTCC 227 assessed as growth inhibition by broth microdilution method | ChEMBL. | 23644214 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.